MADHUMEHARI CHURNA IN DIABETES MELLITUS: EXPLORING ITS PHYTOCHEMICAL LANDSCAPE, PHARMACOLOGICAL MECHANISMS AND TRANSLATIONAL POTENTIAL

Diabetes mellitus is a complex metabolic disorder characterized by persistent hyperglycemia and progressive alterations in multiple physiological pathways, which may ultimately contribute to microvascular and macrovascular complications. The multifactorial nature of diabetes has increased interest in therapeutic approaches capable of influencing multiple biological targets simultaneously. Among traditional Ayurvedic preparations, Madhumehari Churna, a polyherbal formulation comprising twelve medicinal botanicals, has traditionally been used in the management of Prameha and diabetes-related disorders. This review critically examines the available evidence concerning its phytochemical composition, proposed pharmacological mechanisms, therapeutic potential, and safety considerations. The constituent botanicals of Madhumehari Churna contain diverse classes of bioactive compounds, including flavonoids, phenolic acids, tannins, alkaloids, terpenoids, triterpenoids, saponins, glycosides, polysaccharides, and dietary fibres. Experimental studies of its individual constituents suggest potential effects on carbohydrate digestion and absorption, insulin secretion and sensitivity, glucose utilization, lipid metabolism, oxidative stress, and inflammatory signaling. These findings provide a pharmacological rationale for the traditional use of the formulation; however, an important proportion of the available mechanistic evidence is derived from individual herbs or their phytoconstituents rather than from the complete Madhumehari Churna formulation. Therefore, the reported activities should be interpreted as potentially complementary pharmacological effects rather than established synergistic actions. Available clinical evidence remains limited and is characterized by variation in study design, formulation, dosage, treatment duration, and outcome assessment. Similarly, formulation-specific toxicological, pharmacokinetic, and standardization data are comparatively scarce. Further well-designed preclinical investigations and adequately powered clinical studies, together with systematic quality-control and phytochemical standardization, are required to establish the efficacy, safety, reproducibility, and clinical relevance of Madhumehari Churna in diabetes management. Such evidence will help determine its potential role as a multi-component therapeutic approach within contemporary diabetes care.

• Anwar S, Kausar MA, Parveen K, Zahra A, Ali A, Badraoui R, et al. Polyherbal formulation: The studies towards identification of composition and their biological activities. J King Saud Univ Sci., 2022; 34(8): 102256. doi: 10.1016/j.jksus.2022.102256. 
• Dixit S, Rawat N, Jaiswal S. Polyherbal Formulations: A Comprehensive Review of Trending Synergistic Combinations. Iconic Research and Engineering Journals. 2026; 9(7): 338–344. doi:10.64388/IREV9I7-1713376. 
• Mhaske S, Borde A, Tathe PR, Sitaphale GR. Combination of Herbal Formulations: A Comprehensive Review. International Journal of Pharmaceutical Sciences, 2025; 3(6). 
• Zainulabdeen K, Younus RW, Ismael S, Mohammed AH, Bufaroosha M, Al-Sarraj E. Herb Composites in Medicinal Applications: Synergistic Formulations and Historical Foundations. Molecules, 2025. 
• Adewale OB. Biological Properties of Polyherbal Formulations: A Review of their Antimicrobial, Anti-Inflammatory, Antioxidant and Toxicological Activities. Pharmacognosy Journal, 2023. 
• Patankar SB, Gorde A, Joshi K, Suryawanshi K, Soni P, Shah T, et al. Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial. J Ayurveda Integr Med., 2022; 13(4): 100653. doi: 10.1016/j.jaim.2022.100653. 
• Gupta MK, Khade MA, Srivastava B, Hyam SR, Khade AB. A Comprehensive Review of the Marketed Antiulcer Polyherbal Formulations. Int J Life Sci Pharma Res., 2022; 12(6): P77–P86. doi:10.22376/ijpbs/lpr.2022.12.6. P77-86.
• Ministry of Health and Family Welfare, Government of India. The Ayurvedic Formulary of India. Part III. New Delhi: Department of AYUSH, 2011.
• Bhatnagar M, Sharma R, Sharma P, et al. Aryavaidyan. 2024; Analytical and clinical evaluation of Madhumehari Churna. (Use the complete citation exactly as it appears in your source because Aryavaidyan publishes multiple issues each year.)
• Sharma R, Sharma PV, et al. Standardization and pharmacognostic evaluation of Madhumehari Churna. J Ayurveda Integr Med., 2023.
• Gupta P, Singh A, Sharma V, et al. Phytochemical profiling and antidiabetic potential of Madhumehari Churna: Recent advances. J Ethnopharmacol, 2024.
• Asanaliyar M, Nadig P. Syzygium cumini (Jamun) therapeutic potential: a comprehensive review on phytochemical constituents and emphasis on its pharmacological actions related to diabetic intervention. Int J Basic Clin Pharmacol, 2020; 9(2): 363-370. doi:10.18203/2319-2003.ijbcp20200192. 
• Ayyanar M, et al. Antidiabetic effects of Syzygium cumini leaves: a non-hemolytic plant with potential against oxidation, glycation, inflammation and digestive enzyme catalysis. J Ethnopharmacol, 2020; 261: 113132. doi: 10.1016/j.jep.2020.113132. 
• Pujiastuti E, Nugroho AE, Nisa K, Hertiani T. Revealing the contribution of phytochemicals in Syzygium cumini as antidiabetics: a systematic review. Indones J Pharm, 2023. doi:10.22146/ijp.6812.
• Villas Boas GR, Lemos JMR, de Oliveira MW, et al. Aqueous extract from Mangifera indica Linn. (Anacardiaceae) leaves exerts long-term hypoglycemic effect, increases insulin sensitivity and plasma insulin levels on diabetic Wistar rats. PLoS One., 2020; 15(1): e0227105. doi: 10.1371/journal.pone.0227105. PMID:31986177.
• Yoopum S, Wongmanee N, Rojanaverawong W, Rattanapunya S, Sumsakul W, Hanchang W. Mango (Mangifera indica L.) seed kernel extract suppresses hyperglycemia by modulating pancreatic β-cell apoptosis and dysfunction and hepatic glucose metabolism in diabetic rats. Environ Sci Pollut Res Int., 2023; 30(59): 123286-123308. doi:10.1007/s11356-023-31066-7. PMID:37981611.
• Cortez-Navarrete M, Méndez-del Villar M, Ramos-González EJ, Pérez-Rubio KG. Momordica charantia: a review of its effects on metabolic diseases and mechanisms of action. J Med Food., 2021; 24(10): 1011-1032. doi:10.1089/jmf.2020.0206.
• Gaonkar VP, Hullatti KK. Indian traditional medicinal plants as a source of potent antidiabetic agents: a review. J Diabetes Metab Disord, 2020; 19(2): 1895-1908.
• Oyelere SF, Ajayi OH, Ayoade TE, Pereira GBS, Owoyemi BCD, Ilesanmi AO, et al. A detailed review on the phytochemical profiles and anti-diabetic mechanisms of Momordica charantia. Heliyon, 2022; 8(4): e09253. doi: 10.1016/j.heliyon. 2022.e09253. PMID:35434401.
• Cicek SS. Momordica charantia L.—Diabetes-related bioactivities, quality control, and safety considerations. Front Pharmacol, 2022; 13: 904643. doi:10.3389/fphar.2022.904643. PMID:35656300.
• Tiwari P, Mishra BN, Sangwan NS. Gymnema sylvestre: an alternative therapeutic agent for management of diabetes. J Appl Pharm Sci., 2021; 11(5): 1-12.
• Gaonkar VP, Hullatti KK. Indian traditional medicinal plants as a source of potent antidiabetic agents: a review. J Diabetes Metab Disord, 2020; 19(2): 1895-1908. doi:10.1007/s40200-020-00628-8. PMID:33520674.
• Geberemeskel GA, Debebe YG, Nguse NA. Antidiabetic effect of fenugreek seed (Trigonella foenum-graecum) extracts: a systematic review of preclinical and clinical studies. Diabetes Metab Syndr Obes., 2019; 12: 2975-2986. doi:10.2147/DMSO.S236511. PMID:31819519.
• Gaonkar VP, Hullatti KK. Indian traditional medicinal plants as a source of potent antidiabetic agents: a review. J Diabetes Metab Disord., 2020; 19(2): 1895–1908. doi:10.1007/s40200-020-00628-8. PMID:33520674.
• Salehi B, Ali B, Rescigno A, et al. The therapeutic potential of Azadirachta indica: a comprehensive review. Phytother Res., 2021; 35(12): 6627–6649. doi:10.1002/ptr.7306.
• Khatik GL, Saini N, Singh B, et al. Antidiabetic potential of Azadirachta indica: a review of preclinical and clinical evidence. J Ethnopharmacol, 2022; 292: 115221. doi: 10.1016/j.jep.2022.115221.
• Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, et al. Bioactive compounds and bioactivities of ginger (Zingiber officinale Roscoe). Foods, 2019; 8(6): 185. doi:10.3390/foods8060185. PMID:31151279.
• El-Ouady F, Lahrach N, Ajebli M, Haidani AE, Eddouks M. Antihyperglycemic effect of the aqueous extract of Foeniculum vulgare in normal and streptozotocin-induced diabetic rats. Cardiovasc Hematol Disord Drug Targets, 2020; 20(1): 54-63. doi:10.2174/1871525717666190612121516.
• Rafieian F, Amani R, Rezaei A, Karaça AC, Jafari SM. Exploring fennel (Foeniculum vulgare): Composition, functional properties, potential health benefits, and safety. Crit Rev Food Sci Nutr., 2024; 64(20): 6924-6941. doi:10.1080/10408398.2023.2176817.
• Alqahtani AS, Hidayathulla S, Rehman MT, ElGamal AA, Al-Mishari AA, Alaidarous M, et al. Phytochemical composition, pharmacological activities, and therapeutic potential of Senna alexandrina (syn. Cassia angustifolia): A comprehensive review. Plants (Basel), 2022; 11(21): 2894. doi:10.3390/plants11212894.
• Singh A, Sharma PK, Garg VK. Therapeutic potential of Cassia angustifolia Vahl: A systematic review of phytochemistry and pharmacological activities. J Herbmed Pharmacol, 2023; 12(3):       349–361.
• Dey P, Chaudhuri TK. Sida cordifolia Linn.: Traditional uses, phytochemistry, pharmacological activities, and toxicological profile—A review. J Ethnopharmacol, 2021; 275: 114137. doi: 10.1016/j.jep.2021.114137.
• Salehi B, Quispe C, Patra JK, et al. Sida species: A comprehensive review on phytochemistry, traditional uses, pharmacology and toxicology. Biomed Pharmacother, 2021; 135: 111215. doi: 10.1016/j.biopha.2020.111215.
• Sharma R, Kaur R, Kumar S. Phytochemical composition and pharmacological potential of Sida cordifolia L.: An updated review. Phytother Res., 2023; 37(6): 2501–2523. doi:10.1002/ptr.7784.
• Rather LJ, Shahid M, Ganie SA, et al. Vachellia nilotica (L.) P.J.H. Hurter & Mabb. (syn. Acacia nilotica): A comprehensive review of its phytochemistry, pharmacological activities and therapeutic applications. J Ethnopharmacol, 2022; 282: 114603. doi: 10.1016/j.jep.2021.114603.
• Salehi B, Sharifi-Rad J, Quispe C, et al. Pharmacological properties and therapeutic potential of Acacia species: An updated review. Biomed Pharmacother, 2021; 141: 111801. doi: 10.1016/j.biopha.2021.111801.
• Barbalho SM, et al. Evidence from a Systematic Review and Meta-Analysis Pointing to the Antidiabetic Effect of Polyphenol-Rich Plant Extracts from Gymnema, Momordica, and Moringa. Cell Mol Biol (Noisy-le-grand). 2022. 
• Gymnema sylvestre as a Multi-Target Antidiabetic Agent: Mechanistic Insights and Metabolic Regulation, 2025. 
• The Potential of Various Herbal Plants for Therapeutic Treatment for Diabetes Management. Ann Natl Acad Med Sci (India), 2025. 
• Mohammed M, et al. A Review on the Traditional Uses, Phytochemicals, and Pharmacology of Momordica cymbalaria. Phytother Res., 2024.
• Bhatnagar S, Yadav K, Bhardwaj S, Sharma K, Raghuvanshi M, Veena. Scientific review of Madhumehari Churna: An Ayurvedic polyherbal formulation used in management of diabetes mellitus. Aryavaidyan, 2025; 38(2): 15–23. 
• Choudhary N, Sekhon BS. Common Ayurvedic, Chinese traditional and Unani antidiabetic formulations: A review. Biomed Pharmacother, 2022; 156: 113911. 
• Sharma A, et al. Clinical evaluation of Madhumehari Churna in Type 2 Diabetes Mellitus. Int J AYUSH, 2025; 14(8): 9–17. 
• Bhoyare N, Sharma SK, Malviya S, Jamshed, Khatarker YK. A clinical study to evaluate the effect of Madhumehari Churna on glycated hemoglobin (HbA1c) in patient of type 2 diabetes mellitus. Int J AYUSH, 2025; 14(8): 9-17. doi: 10.22159/prl.ijayush.v14i08.1477.
• Bhatnagar SK, Yadav K, Bhardwaj S, Sharma K, Raghuvanshi M, et al. Review of Madhumehari Churna: An Ayurvedic polyherbal formulation used in management of diabetes mellitus. Aryavaidyan, 2024; 38(2): 15–23.
• Mahajon B, Nath R, Gautam MK, Mondal S, Bora M, Gangwar M. Ayurveda medicines and safety apprehension: Need to incite Ayurpharmacoepidemiology. Curr Drug Saf., 2025; 11(6): e22150838299739.
• Hazra S, Singh PA. Safety aspects of herb interactions: Current understanding and future prospects. Curr Drug Metab., 2024; 25(1): 28–53.
• Rasheed H, Ahmed S, Sharma A. Changing trends towards herbal supplements: An insight into safety and herb-drug interaction. Curr Pharm Biotechnol, 2024; 25(3): 285–300.
• Brahma S, Goyal AK, Dhamodhar P, Kumari MR, Jayashree S, Usha T, Middha SK. Can polyherbal medicine be used for the treatment of diabetes? A review of historical classics, research evidence and current prevention programs. Curr Diabetes Rev., 2024; 20(2): e140323214600. 
• Wani VK, Jain R, Verma S, Rajak H. A review on potentiation of polyherbal formulation for the treatment of hyperglycemia and inflammation. Front Health Inform, 2025. 
• Verma S, Pande MS, Mehra RK, Kajla D, Sharma A, Mannan A, et al. Anti-diabetic potential of traditional herbal drugs in polyherbal formulation: A review. J Pharm Technol Res Manag, 2024. 
• Dey YN, et al. Effectiveness of polyherbal formulations for the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis. J Ayurveda Integr Med., 2021; 12: 347–356.